INTRODUCTION 1
Ischemic heart disease is still one of the major causes of global morbidity and mortality since current 2 therapies are not able to repair the damaged heart muscle [4] . Recent developments in stem cell 3 biology and regenerative medicine show promise to replace the lost myocardium with functional 4 healthy tissue [27] . Various stem cell types such as induced pluripotent stem cells [38] , mesenchymal 5 stem cells (MSCs) [18] and cardiac stem cells (CSCs) [2, 40] have shown potential to improve heart 6 function after myocardial infarction (MI). Most beneficial effects observed so far were mediated by 7 paracrine actions, as stem cells secrete cytokines, growth factors and miRNAs that promote 8 cardioprotection, angiogenesis and activate resident CSCs. However, only moderate therapeutic effects 9
were observed in clinical trials. This can be explained by limited differentiation of these stem cells 10 towards cardiomyocytes [15] . 11
Recently, our research group identified a new CSC type in the adult human heart based on high 12 aldehyde dehydrogenase (ALDH) enzyme activity, known as the cardiac atrial appendage stem cell 13 (CASC) [22] . These CASCs are able to preserve left ventricular function in a Göttingen minipig 14 infarction model based on extensive cardiomyogenic differentiation and functional integration [12, 15 22] . Moreover, CASCs can be expanded to clinically relevant cell numbers [42] , making them a 16 perfect candidate for myocardial regeneration. However, to fully restore cardiac function, 17 revascularization of the infarcted tissue is essential. Current catheter-based interventions and surgical 18 bypass procedures are often not successful in reestablishing myocardial blood flow in MI patients, 19
leading to an increased mortality and a poor clinical outcome [3] . In addition, cells transplanted in the 20 infarct area end up in an ischemic environment, implicating that new blood vessel formation is 21 necessary for their successful survival, engraftment and differentiation [36] . Ideally, cell-based 22 therapies should therefore focus on both cardiomyogenesis and angiogenesis to induce optimal repair 23 of the heart muscle. This study explores a possible contribution of CASCs in myocardial angiogenesis 24 by investigating expression of pro-and anti-angiogenic factors and their role in three consecutive steps 25 of the angiogenesis process (endothelial proliferation, migration, tube formation). Stimulation of 26
Immunofluorescence for angiogenic growth factors 1
CASCs were cultured on glass coverslips and fixed in 4% paraformaldehyde (PFA) at 80% 2 confluence. The cells were incubated overnight with a rabbit polyclonal anti-VEGF (1:100; R&D 3 systems), a rabbit anti-IGFBP-3 (1:100; R&D systems) or a mouse anti-ET1 (1:100; Abcam) antibody 4 at 4°C in PBS 0.3% Triton. An Alexa Fluor 594 goat anti-rabbit antibody or an Alexa Fluor 555 goat 5
anti-mouse antibody (1:500; life technologies) was used as secondary antibody. Nuclei were stained 6 with 4′,6-diamidino-2-phenylindole (DAPI). Pictures were taken with a Nikon Eclipse 80i fluorescent 7 microscope and a Nikon DS-2MBWc digital camera. 8
Western blot 9
After heat denaturation, protein lysates were separated on 4-15% Protean® TGX TM Gels and 10 transferred to 0.2µm Transblot® Turbo TM nitrocellulose membranes with the Transblot® Turbo 
11
Transfer System (all from Bio-rad, Temse, Belgium). Blots were blocked in Odyssey blocking buffer 12 (Li-Cor) and primary antibodies used for western blot analysis included a rabbit anti-ET1 antibody 13
(1:500; Abcam), a rabbit anti-IGFBP-3 antibody (1:300; Santa Cruz Biotechnology, Heidelberg, 14 Germany) and a rabbit anti-VEGF antibody (1:300; Santa Cruz Biotechnology). A mouse anti-alpha-15 tubulin antibody (1:5000, Abcam) was used for the loading control. Secondary antibodies were a goat 16 polyclonal anti-rabbit IR-Dye 800CW and a goat polyclonal anti-mouse IRDye 680CW antibody 17
(1:15000; Li-Cor). Detection was performed using an Odyssey Infrared Imaging System (Licor). 
Chorioallantoic membrane assay 10
The angiogenic properties of the CASCs were examined in ovo in the CAM assay [5, 19] . Fertilized 11 white leghorn chicken eggs (Gallus gallus) were incubated at 37 °C in a humidified atmosphere. After 12 3 days (E3), 3-4 ml albumen was removed and a small opening was made in the shell. This opening 13 was covered with cellophane tape and the eggs were returned to the incubator. After 6 days (E9), 14 droplets of 30µl phenol red-free growth factor-reduced Matrigel™ (Amsbio, Abingdon, U.K.) were 15 placed on the CAM. Droplets containing 50 000 CASCs were compared with pure Matrigel droplets as 16 a negative control (Neg Contr 1). On the other hand, Matrigel mixed 1:1 with 20X CASC CM or 20X 17
LG-DMEM 2% P/S 0% FBS (Neg Contr 2) was analyzed. On E12, the CAM was carefully removed 18 from the eggs and pictures were taken. To quantify angiogenesis, two concentric circles (radii 3 and 4 19 mm) were drawn and intersecting blood vessels were counted by 2 independent researchers in a 20 double-blind fashion. The assay was performed 3 times on CASCs and with CM from 6 different 21 were fitted as random effects. Experiment was included as random effect to take variability between 6 experiments into account. CM sample was included as random effect parameter since a paired relation 7
exists between CM and CM with antibodies of the same patient sample. For the CAM assay only 8 experiment was modeled as random effect. The different test conditions are compared using 9
CONTRAST statements. For the functional HMEC-1 assays, a Bonferroni correction for multiple 10 comparisons was implemented based on relevant comparisons between the test conditions of the 11 functional assays. A global significance level of 5% is considered. Bonferroni correction for the 12 multiple comparisons of the functional HMEC-1 assays resulted in a p-value of 0.004. 13
RESULTS 1

CASCs secrete numerous angiogenic growth factors 2
To investigate a possible paracrine effect of CASCs on angiogenesis, we first determined their 3 expression and secretion of important angiogenic growth factors. Numerous anti-(red) and pro-4 angiogenic (green) factors were identified in CASC CM by a human angiogenesis array, whereas no 5 growth factors were detected in the negative control that was not conditioned by CASCs (Fig 1a) . 6
Based on consistent high relative expression levels, the pro-angiogenic growth factors ET-1, IGFBP-3 7 and VEGF were further investigated. ELISA revealed high concentrations of all three factors in CASC 8 CM, while the levels for the negative and positive control were below detection limit or neglectible 9 (Fig 1b) . CASC lysates contained substantially lower growth factor concentrations (Fig 1b) compared 10 to CM. Expression of ET-1, IGFBP-3 and VEGF in CASCs was further confirmed by 11 immunofluorescence in the cells (Fig 1c) and Western blot in lysates (Fig 1d) . CASCS thus express 12 and secrete factors that can positively influence the angiogenesis process. 13 14
CASCs promote HMEC-1 angiogenesis in vitro by the secretion of ET-1, IGFBP-3 and VEGF 15
Next we explored the effects of CASC CM on main steps of the angiogenesis process. It was 16 demonstrated that the different test conditions did not affect HMEC-1 viability (Fig S2) , confirming 17 that effects on HMEC-1 survival did not negatively influence the results. Subsequently, the effects of 18 CASC CM on HMEC-1 proliferation, migration and tube formation were studied. Involvement of the 19 individual factors ET-1, IGFBP-3 and VEGF was assessed by pre-incubating CASC CM with 20 inhibitory antibodies against these factors. CM incubated with isotype control antibodies (ISO) was 21 included to rule out any non-specific influences. In all assays, serum-free medium that was not 22 conditioned by CASCs served as negative control medium (Neg Contr). Medium containing 10% 23 serum as positive control medium (Pos Contr), except for the tube formation assay where HMEC-1 24 culture medium served as positive control. 25 EC proliferation was investigated in an MTT assay and by Ki-67 immunofluorescence. HMEC-1 26 proliferation was increased after incubation with the positive control and CASC CM compared to the 1 negative control in both the Ki-67 (Fig 2a,b; p-value 0.0004 and 0.0006 respectively) and the MTT 2 assay (Fig 2c; p-value <0.0001 and 0.0038 respectively). Inhibition of VEGF reduced the effect of 3 CASC CM in the Ki67 assay (Fig 2b; p-value <0.0001) , while for the MTT assay only combined 4 inhibition of ET-1, IGFBP-3 and VEGF led to a significant decrease (Fig 2c; p-value 0.0032) . 5
However, a clear trend was observed for all inhibitory antibodies in both assays and significance was 6 reached while omitting the bonferoni correction. 7
To study the role of CASC CM in EC migration, a transwell migration assay was performed (Fig 3) . 8
Our results showed that HMEC-1 migration was 4.3 times higher for CASC CM compared to the 9 negative control (p-value <0.0001), although the response was not that strong as the positive control. 10
Incubation of the CM with antibodies against ET-1, IGFBP-3 or VEGF alone significantly diminished 11 these effects (p-value <0.0001 for all antibodies), with an even stronger response when all three 12 inhibitory antibodies were combined, reducing the migration effect of CASC CM by 2.7 fold (p-value 13 <0.0001). 14 EC assembly into tube-like structures was explored by plating HMEC-1 on Matrigel in control media 15 or CASC CM (Fig 4) . HMEC-1 network formation, expressed as the total tube length, was 16 significantly higher after culturing the cells in the positive control and CASC CM compared to the 17 negative control (p-value 0.0001 and 0.0018 respectively). Pre-incubation of CASC CM with a 18 combination of inhibitory antibodies against ET-1, IGFBP-3 and VEGF significantly reduced HMEC-19 1 network formation (p-value <0.0001), which could not be accomplished by blocking these growth 20 factors individually. 21
These in vitro experiments show that CASCs promote all important steps of the angiogenesis process. 22
The effect seems to be mainly mediated by ET-1, IGFBP-3 and VEGF secretion, although other 23 factors are likely also involved. To confirm the angiogenic effect of both CASCs and CASC CM, an in vivo CAM assay was 2 performed by incubating the CAM with CASCs, CASC CM or negative control samples (Fig 5a Neg  3 Contr 1 = Matrigel; Neg Contr 2 = Matrigel mixed 1:1 with 20X LG-DMEM 2% P/S 0% FBS). After 4 72h, radial growth of blood vessels in a spoke wheel pattern towards the droplets was visible for all 5 conditions (Fig 5b,c) . Quantification of the number of blood vessels, based on intersection with two 6 concentric circles (Fig 5b) , revealed a significant increase in blood vessels for both CASCs and CASC 7 CM compared to their negative control (Fig 5d) . The number of blood vessels increased from 22.4 to 8 26.3 (inner circle; p-value 0.0364) and from 29.2 to 37.0 (outer circle; p-value 0.0011) for the negative 9 control compared to CASCs respectively. For CASC CM an augmentation was observed from 18.9 to 10 23.3 (inner circle; p-value 0.0102) and from 29.1 to 32.5 (outer circle; p-value 0.0202) respectively. 11
These results indicate that both CASCs and CASC CM promote blood vessel formation in vivo. 12 13
DISCUSSION 1
We have previously shown that CASCs, as one of the few CSC types, preserve cardiac function in a 2 minipig MI model based on extensive engraftment and cardiomyogenic differentiation [12] . However, 3 not only replacement of the lost heart muscle, but also new blood vessel formation is essential to 4 restore cardiac function. This ensures the supply of critical oxygen and nutrients to the ischemic heart 5 tissue, and guarantees the survival and engraftment of the transplanted progenitor cells [3] . 6
Vasculogenesis and angiogenesis are the main mechanisms for new blood vessel formation, while 7 arteriogenesis enhances blood flow by increasing the luminal diameter of existing arteries [7] . 8
Vasculogenesis by EC differentiation and vascular integration has been described for e.g. endothelial 9
progenitor cells (EPCs) [25] , MSCs [20] and CSCs [2] . In contrast, EC differentiation was only rarely 10 observed (<1%) after CASC transplantation in a minipig MI model, which is in agreement with the 11 strong cardiomyogenic potential of CASCs. Regardless of this observation, an increase in blood vessel 12 density in ischemic areas with transplanted CASC was observed, suggesting a role for CASCs in 13 myocardial angiogenesis [12] . Hence, in line with the emerging paracrine hypothesis for stem cell-14 induced myocardial repair, possible paracrine angiogenic effects of CASCs were explored in this 15
study. 16
Angiogenesis, characterized by the formation of new blood vessels via the branching or elongation of 17 preexisting vessels, is tightly regulated by a balance of both pro-and anti-angiogenic mediators [7] . 18
Numerous angiogenic inducers could be identified in CASC CM after an initial screening. , 19 -3 [16] and VEGF [6, 28] were selected for further analysis, because of high expression levels 20 in CASC CM. Their concentration in CASC lysates was consistently lower compared to the CM, as 21 previously reported for MSCs [31] . This might already suggest a strong paracrine angiogenic potential 22
IGFBP
for CASCs by the secretion of high levels of angiogenic proteins. The concentration of VEGF, as most 23 widely studied angiogenic growth factor, is markedly higher in CASC CM compared to other stem 24 cells types [19, 24] . However, direct comparison of growth factor concentrations in stem cell CM is 25 not feasible, because of differences in the preparation of CM. 26
The importance of VEGF, IGFBP-3 and ET-1 in neovascularization further confirms a likely 27 involvement of these mediators in CASC-induced myocardial angiogenesis. VEGF is one of the most 1 studied angiogenic factors and is involved in almost all steps of the angiogenesis process [6, 28] . 2 IGFBP-3 has been reported to have inhibitory effects in tumor angiogenesis [26] , while pro-3 angiogenic effects have been shown in human umbilical vein ECs [16] . ET-1 is a mitogen for vascular 4 cells and promotes EC migration and tube formation [37] . Despite high relative expression levels of 5 ANG and urokinase plasminogen activator (uPA), these factors were not investigated here as no 6 suitable blocking antibodies were available. The role of all identified growth factors in angiogenesis 7 can be found in Table S2 . A wide variety of angiogenic growth factors are known to be secreted by 8 various stem cell types, such as fibroblast growth factor, hepatocyte growth factor, interleukins and 9 [6, 10, 29, 30] . Other reparative processes have also been shown to be influenced by these 10 secreted growth factors, which also seem likely for the identified CASC secreted mediators. Indeed, 11
VEGF
VEGF reduces inflammation and promotes cardioprotection [6], while MCP-1 attracts monocytes and 12
macrophages, which clear the infarct area from dead cells and debris leading to activation of reparative 13 pathways [13] . 14 Undoubtedly, the identified factors are involved in important steps of angiogenesis and therefore in 15 vitro assays with HMEC-1 were performed to establish the functional pro-angiogenic effects of 16
CASCs. EC proliferation is one of the first important steps in neovascularization and can best be 17 investigated by a combination of cell number quantification and cell cycle analysis [39] . Both our 18 experiments indicated that CASC CM stimulates an increase in HMEC-1 proliferation. Neutralization 19 of VEGF reduced the effect of CASC CM in the Ki67 assay (Fig 2B; p-value <0.0001), while for the 20 MTT assay only combined inhibition of ET-1, IGFBP-3 and VEGF led to a significant decrease (Fig  21   2C ; p-value 0.0032). Discrepancy between the observed results can be explained by the different 22 approach of the assays to assess proliferation. The Ki-67 assay quantifies the number of actively 23 proliferating cells, while the MTT is a measure of the total number of cells and their metabolic 24 activity. Still, a clear trend towards a reduction in HMEC-1 proliferation was observed for all 25 inhibitory antibodies in both assays and significance could be reached for all antibody conditions 26 without Bonferroni correction. Bonferroni correction is known to reduce the statistical power of the 27 test significantly [14] . Our data hence suggest ET-1, IGFBP-3 and VEGF to be important mediators of 1 CASC-induced HMEC-1 proliferation. The proliferative effect of CASC CM was reduced to baseline 2 levels in most antibody conditions. This clearly demonstrates the importance of these specific 3 mediators in the delicate balance of pro-and anti-angiogenic proteins. Similar effects on EC 4 proliferation have also been reported for CM obtained from various MSC types in vitro [11, 21, 35 ] 5 and fetal aorta-derived CD133+ progenitor cells in vivo [1] , while no proliferative effect was observed 6 for dental stem cells (DSCs) [5, 19] . 7
After the proliferation phase, ECs migrate towards chemotactic stimuli. In a transwell system, we were 8 able to show that CASC CM induced similar HMEC-1 migration as the positive control. Individual 9 inhibition of ET-1, IGFBP-3 and VEGF reduced this process, which was enhanced when combining 10 the three inhibitory antibodies. This demonstrates that ET-1, IGFBP-3 and VEGF are all important 11 mediators of CASC-induced EC chemotaxis. Despite this promising result, the effect of CASC CM 12
was not completely reduced. This suggests that other factors are also involved in EC chemotaxis as 13 shown in migration assays for EPCs [41] , MSCs [11, 35] , DSCs [5, 19] and other CSC types [43] . 14 As a last step in the angiogenesis process, migrating ECs assemble into tube-like structures that form 15 the base of the newly formed blood vessels, which was assessed in a Matrigel tube formation assay. 16
Our results indicated that CASC CM improved HMEC-1 network formation as previously reported for 17
MSCs [17] , DSCs [5, 19] and other CSCs [9] . Only combined inhibition of ET-1, IGFBP-3 and VEGF 18 reduced HMEC-1 tube formation to baseline levels, pointing towards a synergistic effect. Moreover, a 19 dose-dependent effect on HMEC-1 tube formation was demonstrated as shown in supplementary 20 figure S3 . 21
Although CASCs stimulate the main phases of neovascularization, the formation of functional blood 22 vessels requires successful occurrence of all subsequent steps of the angiogenesis process with 23 complex interactions between ECs, pericytes or smooth muscle cells and stromal cells. Therefore, a 24 CAM assay was performed to confirm the angiogenic effects of the CASCs in vivo. The CAM is a 25 highly vascularized extraembryonic membrane which serves as a gas exchange surface of the chicken 26 embryo. As the chick immune system is not fully established until late stages of development, the 27 embryo serves as a naturally immunodeficient host capable of sustaining grafted mediators and cells 1 without species-specific restrictions [33] . Moreover, the CAM can be easily manipulated and 2 observed, making it an ideal model to study angiogenesis in vivo [34] . Both CASCs and CASC CM 3 promoted angiogenesis as observed by extensive radial ingrowth of blood vessels. Although CASC 4 CM was concentrated 10X, similar effects were observed for CASCs and CASC CM. This can be 5 explained by the continuous production of angiogenic growth factors by CASCs, while CM or single 6 protein administrations require higher doses because of a short protein half-life [32] . Similar results 7
were observed in CAM assays with DSCs [5, 19] bone marrow stromal cells [17] and placental MSCs 8
[23]. 9
In conclusion, CASC, isolated from atrial appendages of MI patients, stimulate angiogenesis in vitro 10 and in vivo. was repeated 16 independent times with Neg Contr n=17, Pos Contr n=20, CASC CM n=28, ISO n=3, 7
aET-1 n=20, aIGFBP-3 n=18, aVEGF n=15, aE+I+V n=9. * significance compared to Neg Contr; # 8 compared to CASC CM .* or # p-value <0.004. ET-1 endothelin 1, IGFBP-3, insulin-like growth 9 factor binding protein 3, ISO isotype control antibodies, Neg Contr unconditioned serum-free medium, 10
Pos Contr medium with 10% FBS, VEGF vascular endothelial growth factor. Representative pictures of HMEC-1 tubular networks after 24h (A). A significant increase in total tube 3 length was observed for the positive control and CASC CM compared to the negative control (B). 4
Combined inhibition of ET-1, IGFBP-3 and VEGF significantly reduced these effects. Data are 5 expressed as mean±SEM. For the tube formation assay, 14 experiments were performed with Neg 6 Contr n=18, Pos Contr n=14, CASC CM n=25, ISO n=6, aET-1 n=17, aIGFBP-3 n=20, aVEGF n=20, 7 aE+I+V n=13. * significance compared to Neg Contr; # compared to CASC CM.* or # p-value 8 <0.004; ## p-value < 0.0008. ET-1 endothelin 1, IGFBP-3, insulin-like growth factor binding protein 9 3, ISO isotype control antibodies, Neg Contr unconditioned serum-free medium, Pos Contr HMEC-1 10 culture medium with 10% FBS L-Glut hEGF HC, VEGF vascular endothelial growth factor. control for the inner and outer circle. Data are expressed as mean±SEM. The CAM assay was repeated 7 3 independent times with 6 CASC and CASC CM donor samples. * p-value <0.05; ** p-value < 0.01. 8
Neg Contr 1 = Matrigel; Neg Contr 2 = Matrigel mixed 1:1 with serum-free medium. 9
